Search

everythinglearnresearchcommunity

for

Search:↓

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

The UD-PrOZA program successfully diagnosed 18% of adult patients with rare diseases, often using genetic testing.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

A fast and accurate method was developed to measure alfuzosin and dutasteride in human plasma.

The Hair660™ light therapy device effectively and safely improves hair density in people with androgenetic alopecia.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

"Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.

Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.

An 87-year-old man showed unusual signs of Hodgkin lymphoma, primarily high calcium levels, which improved after treatment and revealed the disease.

Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.

PRP is a promising and safe treatment for early to moderate knee osteoarthritis but needs standardized protocols.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

The laser therapy device effectively increased hair growth in people with androgenetic alopecia.

New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.

Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.

Standardized PRP is effective for tendinopathies, with most patients improving after one injection.

Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.

Systemic steroids temporarily improve severe alopecia areata in children but often lead to relapse.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

Temozolomide improves survival in grade III glioma patients without harming quality of life.

Providing housing and case management reduces hospital visits for chronically ill homeless adults.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

New treatments for lupus show promise, but more research is needed, especially for children.

Standardized treatment protocols are needed for children with androgenetic alopecia.

Most patients improved in both atopic dermatitis and alopecia areata with certain treatments, but some had worsened symptoms, suggesting personalized care is needed.